作者: Maria Hauge , Marie A. Vestmar , Anna S. Husted , Jeppe P. Ekberg , Michael J. Wright
DOI: 10.1016/J.MOLMET.2014.10.002
关键词:
摘要: Objectives GPR40 (FFAR1), a clinically proven anti-diabetes target, is Gq-coupled receptor for long chain fatty acids (LCFA) stimulating insulin secretion directly and mediating major part of the dietary triglyceride-induced incretins GLP-1 GIP. In phase-II studies GPR40 agonist TAK-875 decreased blood glucose but surprisingly without incretins.